Enanta reports fiscal Q3 2026 results, dosing underway in pediatric RSV trial
Zelicapavir advances in both pediatric and adult RSV programs while Enanta guides cash runway into fiscal 2029.
SEC filing
Latest
2 stories
Sign inSign in2 stories
Zelicapavir advances in both pediatric and adult RSV programs while Enanta guides cash runway into fiscal 2029.
SEC filing